Clinical Trial Update: A Study of Anlotinib Combined With AK105 Injection in Subjects With Microsatellite Instability-High (MSI-H) or Mismatch Repair Deficient (dMMR) Advanced Solid Tumor [Phase 2]

View source ↗

Summary

Phase 2 trial evaluating the combination of Anlotinib with AK105 injections in MSI-H or dMMR advanced solid tumors.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Mismatch Repair Deficient Cancers
• Msi-h
• Solid Tumors

Drugs mentioned

• AK105 (anti-PD-1 monoclonal antibody)
• Anlotinib (anlotinib)

Snippet

Sponsor: Chia Tai Tianqing Pharmaceutical Group Co., Ltd. | Conditions: MSI-H or dMMR Advanced Solid Tumors | Phase 2 | Status: UNKNOWN